Mablink was founded in 2018 following its discovery of the disruptive PSARlink™ hydrophilic ADC technology, which addresses most of the technological barriers currently slowing down the translation of ADCs from the laboratory bench to the patients. We apply the PSARlink™ technology to our own pipeline of ADCs but we also want other ADC developers to take advantage of PSARlink™ for their programs.

We are therefore welcoming partnering inquiries so that more patients can benefit from new and better treatments.